{"id":356584,"date":"2023-06-21T01:00:00","date_gmt":"2023-06-20T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=356584"},"modified":"2023-04-26T17:00:31","modified_gmt":"2023-04-26T15:00:31","slug":"dupilumab-proves-itself-in-daily-practice","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/dupilumab-proves-itself-in-daily-practice\/","title":{"rendered":"Dupilumab proves itself in daily practice"},"content":{"rendered":"\n
In the “BioDay Registry” study, treatment with dupilumab in pediatric patients with atopic dermatitis in a “real world” setting resulted in significant improvement in disease severity and associated symptoms. Tolerability was found to be good, and the safety profile is consistent with results from clinical trials.<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Dupilumab has been shown to be an effective and safe treatment for atopic dermatitis (AD) to date [1]. By binding to the IL-4R\u03b1 subunit of the IL-4 and IL-13 receptor complexes, the monoclonal antibody specifically inhibits the proinflammatory effects of these two key cytokines [1]. In Switzerland, dupilumab (Dupixent\u00ae<\/sup>) is approved for patients with AD aged 6 years and older [1]. To investigate the treatment effects of dupilumab in pediatric AD patients in a “real world” setting, the “BioDay Registry” study was conducted [2]. In this prospective cohort study, dupilumab-treated children (\u22656 to <12 years) and adolescents (\u226512 to <18 years) with moderate to severe AD were studied. Patients with a body weight <60 kg received dupilumab (s.c.) every two weeks (q2w) after an initial loading dose of 400 mg. In patients with a body weight \u226560 kg, 600 mg was administered as a loading dose, followed by 300 mg q2w. Children weighing 15-60 kg received 300 mg at baseline and after 2 weeks, and then 300 mg dupilumab every four weeks. Concomitant treatment with topical corticosteroids was allowed. <\/p>\n\n

<\/p>\n

\n
\"\"<\/a><\/figure>\n<\/div>\n

At the survey time points in week 0 (baseline) and in week 4, 16 and 28 the severity of the disease was assessed by validated scores: “Eczema Area and Severity Index” (EASI), “Investigator Global Assessment” (IGA), “Numeric Rating Scale” (NRS) for itching and pain, “Patient-Oriented Eczema Measure” (POEM) [2]. In addition, serum biomarkers associated with severity were measured. <\/p>\n\n

<\/p>\n

\n
\"\"<\/a><\/figure>\n<\/div>\n

Of the 61 patients included, 75.4% and 49.2% achieved an EASI-50 and EASI-75 response, respectively (Fig. 1) <\/strong>[2]. The EASI-90 response rate was 24.6%. Lesion-free or nearly lesion-free according to the IGA score was 36.1%. An improvement of \u22654 points in POEM was achieved by 84.7%, whereas this proportion was 45.3% and 77.4% for NRS itch and NRS pain, respectively. Biomarkers TARC, PARC, periostin, sIL-2Ra, and eotaxin-3 decreased significantly during treatment. The p-EASI showed a significant correlation with disease severity. The most common adverse events were conjunctivitis (n=10) and headache (n=4) (Table 1<\/strong>).<\/p>\n\n

Literature:<\/p>\n\n

    \n
  1. Drug Information, www.swissmedicinfo.ch,<\/a>(last accessed 04\/13\/2013).<\/li>\n\n\n\n
  2. Kamphuis E, et al: Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Pediatr Allergy Immunol 2022; 33(12): e13887.<\/li>\n<\/ol>\n\n

    DERMATOLOGY PRACTICE 2023; 33(2): 52<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    In the “BioDay Registry” study, treatment with dupilumab in pediatric patients with atopic dermatitis in a “real world” setting resulted in significant improvement in disease severity and associated symptoms. Tolerability…<\/p>\n","protected":false},"author":7,"featured_media":30707,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Atopic dermatitis in childhood and adolescence","footnotes":""},"category":[11331,11340,11508,11437,11548,11503],"tags":[12624,67848,66577,27666,13405,16209,67847,17874,26040],"powerkit_post_featured":[],"class_list":["post-356584","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allergology-and-clinical-immunology","category-dermatology-and-venereology","category-education","category-pediatrics","category-rx-en","category-studies","tag-atopic-dermatitis-en","tag-bioday-registry","tag-childhood-and-adolescence","tag-compatibility","tag-dupilumab-en","tag-dupixent-en","tag-pediatric-patients","tag-real-world-en","tag-severity","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-19 08:10:40","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":356595,"slug":"dupilumab-fait-ses-preuves-dans-la-pratique-quotidienne","post_title":"Dupilumab fait ses preuves dans la pratique quotidienne","href":"https:\/\/medizinonline.com\/fr\/dupilumab-fait-ses-preuves-dans-la-pratique-quotidienne\/"},"it_IT":{"locale":"it_IT","id":356615,"slug":"dupilumab-si-dimostra-valido-nella-pratica-quotidiana","post_title":"Dupilumab si dimostra valido nella pratica quotidiana","href":"https:\/\/medizinonline.com\/it\/dupilumab-si-dimostra-valido-nella-pratica-quotidiana\/"},"pt_PT":{"locale":"pt_PT","id":356456,"slug":"o-dupilumab-prova-a-sua-eficacia-na-pratica-diaria","post_title":"O dupilumab prova a sua efic\u00e1cia na pr\u00e1tica di\u00e1ria","href":"https:\/\/medizinonline.com\/pt-pt\/o-dupilumab-prova-a-sua-eficacia-na-pratica-diaria\/"},"es_ES":{"locale":"es_ES","id":356468,"slug":"dupilumab-demuestra-su-eficacia-en-la-practica-diaria","post_title":"Dupilumab demuestra su eficacia en la pr\u00e1ctica diaria","href":"https:\/\/medizinonline.com\/es\/dupilumab-demuestra-su-eficacia-en-la-practica-diaria\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/356584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=356584"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/356584\/revisions"}],"predecessor-version":[{"id":356593,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/356584\/revisions\/356593"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/30707"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=356584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=356584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=356584"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=356584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}